Literature DB >> 20494524

Altered fractionation in radiotherapy: from radiobiological rationale to therapeutic gain.

Loredana G Marcu1.   

Abstract

The implementation of altered fractionation schedules in clinical practice came as a need to improve loco-regional control and survival in those cancer patient groups which did not respond satisfactorily to conventionally fractionated radiotherapy. The current review aims to present the radiobiological rationale behind various non-conventional treatment schedules including the encountered challenges, through a compilation of clinical studies/trials and their contribution towards therapeutic gain.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Year:  2010        PMID： 20494524     DOI： 10.1016/j.ctrv.2010.04.004

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


  14 in total

1.  Hypofractionated stereotactic radiosurgery for large-sized skull base meningiomas.

Authors:  Hyuk-Jin Oh; Young Hyun Cho; Jeong Hoon Kim; Chang Jin Kim; Do Hoon Kwon; Doheui Lee; KyoungJun Yoon
Journal:  J Neurooncol       Date:  2020-07-01       Impact factor: 4.130

2.  Role of a DNA damage checkpoint pathway in ionizing radiation-induced glioblastoma cell migration and invasion.

Authors:  Issai Vanan; Zhiwan Dong; Elena Tosti; Gregg Warshaw; Marc Symons; Rosamaria Ruggieri
Journal:  Cell Mol Neurobiol       Date:  2012-05-03       Impact factor: 5.046

3.  Ionizing radiation: mechanisms and therapeutics.

Authors:  Cristina M Furdui
Journal:  Antioxid Redox Signal       Date:  2014-05-16       Impact factor: 8.401

4.  The miR-99 family regulates the DNA damage response through its target SNF2H.

Authors:  A C Mueller; D Sun; A Dutta
Journal:  Oncogene       Date:  2012-04-23       Impact factor: 9.867

5.  Effects of age and radiation treatment on function of extrinsic tongue muscles.

Authors:  John A Russell; Nadine P Connor
Journal:  Radiat Oncol       Date:  2014-12-04       Impact factor: 3.481

6.  PRONTOX - proton therapy to reduce acute normal tissue toxicity in locally advanced non-small-cell lung carcinomas (NSCLC): study protocol for a randomised controlled trial.

Authors:  Sebastian Zschaeck; Monique Simon; Steffen Löck; Esther G C Troost; Kristin Stützer; Patrick Wohlfahrt; Steffen Appold; Sebastian Makocki; Rebecca Bütof; Christian Richter; Michael Baumann; Mechthild Krause
Journal:  Trials       Date:  2016-11-15       Impact factor: 2.279

7.  Loss of p27kip1 increases genomic instability and induces radio-resistance in luminal breast cancer cells.

Authors:  Stefania Berton; Martina Cusan; Ilenia Segatto; Francesca Citron; Sara D'Andrea; Sara Benevol; Michele Avanzo; Alessandra Dall'Acqua; Monica Schiappacassi; Robert G Bristow; Barbara Belletti; Gustavo Baldassarre
Journal:  Sci Rep       Date:  2017-04-04       Impact factor: 4.379

Review 8.  Regulatory mechanisms and clinical perspectives of miRNA in tumor radiosensitivity.

Authors:  Luqing Zhao; Ann M Bode; Ya Cao; Zigang Dong
Journal:  Carcinogenesis       Date:  2012-07-12       Impact factor: 4.944

9.  Photofrin based photodynamic therapy and miR-99a transfection inhibited FGFR3 and PI3K/Akt signaling mechanisms to control growth of human glioblastoma In vitro and in vivo.

Authors:  Mrinmay Chakrabarti; Naren L Banik; Swapan K Ray
Journal:  PLoS One       Date:  2013-02-07       Impact factor: 3.240

10.  Non-standard radiotherapy fractionations delay the time to malignant transformation of low-grade gliomas.

Authors:  Araceli Henares-Molina; Sebastien Benzekry; Pedro C Lara; Marcial García-Rojo; Víctor M Pérez-García; Alicia Martínez-González
Journal:  PLoS One       Date:  2017-06-01       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.